bluebird bio
NEWS
In the latest Ideal Employer Survey, BioSpace readers chimed in their thoughts on which companies across the biotech and biopharma industries were doing the most interesting and meaningful work.
According to the second biennial 2019 Life Sciences Ideal Employer Report by BioSpace, the top three most important attributes cited by life sciences professionals around the world are the opportunity to do interesting and meaningful work, a competitive salary and health benefits.
There are high hopes for more M&A in the industry for the remainder of the year. Here’s a look at the 10 top takeover targets.
Last week there were quite a few clinical trials whose data were presented. Many were at the American Diabetes Association 79th Scientific Sessions, while others were presented at separate meetings or independently. Here’s a look.
Cambridge, Mass.-based bluebird bio released updated results from three clinical trials of its LentiGlobin gene therapy for transfusion-dependent Beta-thalassemia.
This is the largest fund in the 12 years Third Rock has been in existence. The company indicates it will use the money to seed 10 to 12 life science companies.
Celgene Corporation and bluebird bio published interim data from CRB-401, their Phase I trial of bb2121, their CAR-T therapy in patients with relapsed and refractory multiple myeloma.
In the first quarter of 2019, more than 30 life science companies* announced expansions, new locations, increased funding, new trial and product launches and various other news pointing to a growing industry.
The manufacturing plant will produce lentiviral vector for its gene and cell therapies, including bb2121 and bb21217 for multiple myeloma and possibly LentiGlobin for transfusion-dependent beta-thalassemia (TDT) and sickle cell disease.
JOBS
IN THE PRESS
bluebird bio, Inc. announced the pricing of an underwritten public offering of 9,090,910 shares of its common stock at a public offering price of $55.00 per share, before underwriting discounts.
bluebird bio, Inc. announced that it has commenced an underwritten public offering of $400 million of its common stock. bluebird bio also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent of the shares of common stock offered in the public offering.
bluebird bio to Present Data from Its Gene and Cell Therapy Programs During the Virtual Edition of the 25 th European Hematology Association Annual Congress Presentation of new and updated results from ongoing Phase 1/2 HGB-206 study of LentiGlobin for sickle cell disease will include additional patients treated in the study New and updated data, including analysis of healthy red blood cell production in patients with transfusion-dependent β-thalassemia
Bristol Myers Squibb and bluebird bio, Inc. announced updated results from the pivotal, Phase 2 KarMMa study evaluating the efficacy and safety of the companies’ investigational B-cell maturation antigen -directed chimeric antigen receptor T cell immunotherapy, idecabtagene vicleucel, in patients with relapsed and refractory multiple myeloma.
Bristol Myers Squibb to host an investor call today at 8:00 a.m. EDT bluebird bio to host an investor call today at 8:45 a.m. EDT
Bristol Myers Squibb to buy out its ex-U.S. milestone and royalty obligations to bluebird bio for $200 million – - Bristol Myers Squibb assumes responsibility for vector manufacturing in ex-US territories – - bluebird to hold conference call and webcast today, May 11, 2020 at 8:00AM ET – CAMBRIDGE, Mass.--( BUSINESS WIRE )-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that it has amended its existing co-promotion/co-development a
Alignment with FDA on an accelerated regulatory path for LentiGlobin for sickle cell disease based on HGB-206 study with targeted submission in 2H 2021
Hitachi Chemical Advanced Therapeutics Solutions, LLC and apceth Biopharma GmbH, both subsidiaries of Hitachi Chemical Co., Ltd. announced that they have expanded their relationship with bluebird bio with long-term development and manufacturing services agreements for clinical and commercial supply for multiple therapies, including:.
Virtual oral presentation will include updated efficacy and safety data from pivotal Phase 2 KarMMa study of ide-cel- -Biologics License Application under review with U.S. Food and Drug Administration (FDA)- CAMBRIDGE, Mass.--( BUSINESS WIRE )-- bluebird bio, Inc. (Nasdaq: BLUE) announced today that updated results from the pivotal Phase 2 KarMMa study evaluating the efficacy and safety of idecabtagene vicleucel (ide-cel; bb2121), an invest
Errant Gene Therapeutics (“EGT”) announces, that on April 30, 2020, the New York Supreme Court, First Department, Appellate Division unanimously affirmed rulings in EGT’s favor to proceed with fraud, unfair competition, and breach of contract claims in a trial scheduled October 29th, 2020 against Bluebird Bio and Sloan Kettering Institute for Cancer Research (SKI). EGT is represented by Ken Sussmane of McCue Sussmane Zapfel &